SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and…
Thu, 08 May 2025 17:33:00 GMT SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (TSBX), a biotechnology ... Forward-Looking Statements Statements contained in this press release regarding matters that ...
Thu, 08 May 2025 11:00:00 GMT SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a ...
Thu, 08 May 2025 08:00:00 GMT In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to ...
Thu, 17 Apr 2025 12:59:00 GMT In a stark reflection of the challenges facing the biotech sector, Turnstone Biologics Corp. (TSBX) stock has tumbled to a 52-week... Turnstone Biologics Corp. (TSBX) stock has tumbled to a 52 ...
